Biologic Exclusivity Provision In USMCA Is Boon To Generics Industry; BIO Is 'Tremendously Worried'
Revised North American trade deal touted as enabling Congress to address crisis of high drug prices; requirement for 10 years biologic exclusivity is removed and language to allow incentives for generics added.
You may also be interested in...
USMCA is looking more and more like a win for generic firms, who hope it will be template for future trade agreements.
Biologics exclusivity remains a contentious issue as US Trade Representative and House Democrats begin discussions on the trade pact with Mexico and Canada.